Efstathios Kastritis, MD, of the University of Athens, discusses phase III findings of the Andromeda study. Adding daratumumab to cyclophosphamide, bortezomib, and dexamethasone resulted in deeper and more rapid hematologic responses and improved clinical outcomes in patients with newly diagnosed light chain amyloidosis (Abstract LB2604).
Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, w...
Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may ha...
Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphami...
Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide...
Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myelo...
